文献速递流行病学与生物统计基础与转化研究

心脏代谢危险因素与COVID-19易感性和严重性的孟德尔随机化分析

Cardiometabolic risk factors for COVID-19 susceptibility and severity: A Mendelian randomization analysis.
PubMed 文献 · PLoS Med · 2021-03-04

本研究采用两样本孟德尔随机化分析,评估17项心脏代谢特征与COVID-19易感性及严重性的关联。研究发现遗传预测的较高BMI与COVID-19住院风险升高显著相关,而与检测阳性风险关联未达统计学显著;BMI的直接效应在对2型糖尿病、冠心病、卒中和慢性肾脏病的效应进行条件化后消失。

要点

  • 遗传预测BMI每升高1 kg/m²,COVID-19住院风险增加(UK Biobank OR 1.14,95%CI 1.07-1.21)。
  • BMI对COVID-19住院的直接效应在对2型糖尿病、冠心病、卒中和慢性肾脏病条件化后消失。

核心结论

  • 遗传证据支持较高BMI是COVID-19易感性和严重性的因果危险因素。
  • 肥胖可能独立或通过其心脏代谢后果放大COVID-19疾病负担。
  • 针对肥胖可能成为降低重症COVID-19结局风险的策略。

研究设计与样本

  • 两样本孟德尔随机化分析,评估17项心脏代谢特征与COVID-19易感性和严重性的关联。
  • 遗传变异选自全基因组关联研究(GWAS),暴露工具变量在p < 5 × 10-8水平选取。
  • COVID-19易感性和严重性汇总统计来自COVID-19 Host Genetics Initiative GWAS荟萃分析,纳入自报或遗传推断欧洲血统个体。
  • 易感性定义为COVID-19检测阳性,严重性定义为因COVID-19住院 versus 人群对照。
  • 对BMI额外使用UK Biobank效应估计重复分析,并采用成对多变量孟德尔随机化估计直接和间接效应。

主要发现

  • 遗传预测较高BMI与COVID-19检测阳性关联未达统计学显著(14,134例病例/1,284,876例对照,p = 0.002;UK Biobank每kg/m² OR 1.06 [95% CI 1.02, 1.10],p = 0.004)。
  • 遗传预测较高BMI与COVID-19住院风险升高显著相关(6,406例住院病例/902,088例对照,p = 4.3 × 10-5;UK Biobank每kg/m² OR 1.14 [95% CI 1.07, 1.21],p = 2.1 × 10-5)。
  • BMI的直接效应在对2型糖尿病、冠心病、卒中和慢性肾脏病的效应条件化后消失。
  • 其他心脏代谢暴露未显示与更差COVID-19结局风险升高相关。

关键数值与推荐

  • 统计显著性阈值设为p < 0.05/34检验 = 0.0015。
  • BMI与COVID-19检测阳性关联p = 0.002,未达预设显著性阈值。
  • BMI与COVID-19住院关联p = 4.3 × 10-5,达到预设显著性阈值。

临床怎么用

  • 肥胖可作为重症COVID-19风险评估的考量因素。
  • 针对肥胖的干预可能有助于降低重症COVID-19结局风险。
  • BMI对重症COVID-19的影响可能部分通过肥胖相关心脏代谢疾病介导。

局限性

  • 小样本量和弱遗传工具可能限制了对 modest 关联的检测。
  • 多效性可能使效应估计偏离零值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epidemiological studies report associations of diverse cardiometabolic conditions including obesity with COVID-19 illness, but causality has not been established. We sought to evaluate the associations of 17 cardiometabolic traits with COVID-19 susceptibility and severity using 2-sample Mendelian randomization (MR) analyses. METHODS AND FINDINGS: We selected genetic variants associated with each exposure, including body mass index (BMI), at p < 5 × 10-8 from genome-wide association studies (GWASs). We then calculated inverse-variance-weighted averages of variant-specific estimates using summary statistics for susceptibility and severity from the COVID-19 Host Genetics Initiative GWAS meta-analyses of population-based cohorts and hospital registries comprising individuals with self-reported or genetically inferred European ancestry. Susceptibility was defined as testing positive for COVID-19 and severity was defined as hospitalization with COVID-19 versus population controls (anyone not a case in contributing cohorts). We repeated the analysis for BMI with effect estimates from the UK Biobank and performed pairwise multivariable MR to estimate the direct effects and indirect effects of BMI through obesity-related cardiometabolic diseases. Using p < 0.05/34 tests = 0.0015 to declare statistical significance, we found a nonsignificant association of genetically higher BMI with testing positive for COVID-19 (14,134 COVID-19 cases/1,284,876 controls, p = 0.002; UK Biobank: odds ratio 1.06 [95% CI 1.02, 1.10] per kg/m2; p = 0.004]) and a statistically significant association with higher risk of COVID-19 hospitalization (6,406 hospitalized COVID-19 cases/902,088 controls, p = 4.3 × 10-5; UK Biobank: odds ratio 1.14 [95% CI 1.07, 1.21] per kg/m2, p = 2.1 × 10-5). The implied direct effect of BMI was abolished upon conditioning on the effect on type 2 diabetes, coronary artery disease, stroke, and chronic kidney disease. No other cardiometabolic exposures tested were associated with a higher risk of poorer COVID-19 outcomes. Small study samples and weak genetic instruments could have limited the detection of modest associations, and pleiotropy may have biased effect estimates away from the null. CONCLUSIONS: In this study, we found genetic evidence to support higher BMI as a causal risk factor for COVID-19 susceptibility and severity. These results raise the possibility that obesity could amplify COVID-19 disease burden independently or through its cardiometabolic consequences and suggest that targeting obesity may be a strategy to reduce the risk of severe COVID-19 outcomes.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Leong A, Cole JB, Brenner LN, et al. Cardiometabolic risk factors for COVID-19 susceptibility and severity: A Mendelian randomization analysis. PLoS Med. 2021. PMID: 33661905. doi:10.1371/journal.pmed.1003553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。